SUBSCRIBE
SUBSCRIBE
News   Drug Development

Regeneron Pharmaceuticals, Inc. Drug to Lower Gout Flares Meets Goal in Study

September 3, 2008 | 
1 min read
Sept 3 (Reuters) - Regeneron Pharmaceuticals Inc said a mid-stage study of its experimental treatment for gout, Arcalyst, met the main goal and reduced the incidence of gout flares by 81 percent.
Clinical research Phase II
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Sketch image trend artwork montage 3D photo collage of target trader business charts stats young lady hold laptop run up ladder success.
Rare diseases
Kyverna’s CAR T Therapy Delivers ‘Impressive’ Mobility Benefits in Stiff Person Syndrome
December 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Targeting cancer as oncology drugs and oncologist symbol for preventing malignant tumor growth disease as a symbol for pharmaceutical science and immunology or fighting human cancers.
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
December 15, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of businessman running back around
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hypnose eye with sharp lines. Focus illusion.
Autoimmune disease
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong